Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract CD19-directed chimeric antigen receptor T cell therapy (CAR19) improves survival in relapsed/refractory large B cell lymphoma compared with immunochemotherapy with intent for autologous hematopoietic cell transplantation (autoHCT). However, major toxicities include prolonged cytopenias, infection and secondary hematologic malignancies.
Research ArticleTRANSPLANT Stephan Busque1, John D. Scandling2, Robert Lowsky3, Judith Shizuru3, Kent Jensen4, Jeffrey Waters4, Hsin-Hsu Wu3,4, Kevin Sheehan4, Asha Shori1, Okmi Choi5, Thomas Pham1, Marcelo A. Fernandez Vina5, Richard Hoppe6, John Tamaresis7, Philip Lavori7, Edgar G. Engleman5, Everett Meyer3 and Samuel Strober4,* 1Division of Abdominal Transplantation, Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
